We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > TYMLOS

News List

Radius Announces Update on Tymlos (abaloparatide) Label Drugs
December 29, 2021
Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) today announced that the U.S. Food and Drug Administration (FDA) has approved updates to the Tymlos label, including the removal of the boxed warning regarding the risk of osteosarcoma.
Radius Health Announces Commercial Agreement with Paladin Labs for Abaloparatide in Canada americanpharmaceuticalreview
January 13, 2021
Radius Health has entered into definitive agreements with Endo Ventures Limited, a subsidiary of Endo International, to register, commercialize, and distribute abaloparatide on an exclusive basis in Canada.